Primary Outcome Measures
- To set up spheroids models to study and serve as a platform
- To set up spheroids models and serve as a platform
- To set up organoid models
- Test inhibitors on spheroids and organoids and assess the response of individual patients to therapy
Secondary Outcome Measures
- To investigate inhibitors of the CXCR4-CXCL12-HMGB1 axis on the crosstalk
- To investigate inhibitors of the CXCR4-CXCL12-HMGB1 axis on the crosstalk
- To investigate inhibitors of the CXCR4-CXCL12-HMGB1 axis on the crosstalk
Other Outcome Measures
- Repurposing Diflunisal as antitumor drug in MPM
Inclusion Criteria
- Patients with Mesothelioma:
Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma.
- Candidates for surgical intervention.
- Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women.
- Capacity to comprehend the study nature and provide autonomously informed consent.
Control Group patients:
- Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious).
- Candidates for surgical intervention.
- Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women.
- Ability to understand the study nature and provide autonomously informed consent.
If the patient’s diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study.
Exclusion Criteria
- Lack of biopsy material.
- pregnancy.
- Unwillingness to sign the Informed Consent.
